BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33602901)

  • 1. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
    van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
    Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.
    Cremasco F; Menietti E; Speziale D; Sam J; Sammicheli S; Richard M; Varol A; Klein C; Umana P; Bacac M; Colombetti S; Perro M
    PLoS One; 2021; 16(1):e0241091. PubMed ID: 33406104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
    Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
    J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
    Mhibik M; Gaglione EM; Eik D; Herrick J; Le J; Ahn IE; Chiu C; Wielgos-Bonvallet M; Hiemstra IH; Breij ECW; Chen J; Reilly EB; Epling-Burnette PK; Szafer-Glusman E; Sun C; Wiestner A
    Blood Adv; 2023 Aug; 7(15):4089-4101. PubMed ID: 37219524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
    Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
    Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
    Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
    Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly
    Takaura K; Ando H; Ganoza ER
    Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
    Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N
    Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
    Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Andreadis B; Bartlett NL; Budde LE; Caimi PF; Chang JE; Christian B; DeVos S; Dholaria B; Fayad LE; Habermann TM; Hamid MS; Hernandez-Ilizaliturri F; Hu B; Kaminski MS; Karimi Y; Kelsey CR; King R; Krivacic S; LaCasce AS; Lim M; Messmer M; Narkhede M; Rabinovitch R; Ramakrishnan P; Reid E; Roberts KB; Saeed H; Smith SD; Svoboda J; Swinnen LJ; Tuscano J; Vose JM; Dwyer MA; Sundar H
    J Natl Compr Canc Netw; 2023 Nov; 21(11):1118-1131. PubMed ID: 37935098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of bispecific antibodies in relapsed and refractory DLBCL.
    Lewis KL; Cheah CY
    Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epcoritamab: First Approval.
    Frampton JE
    Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
    Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
    Front Immunol; 2019; 10():1943. PubMed ID: 31475004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular lymphoma with progression to diffuse large B-cell lymphoma and concurrent CD5-negative mantle cell lymphoma-3 entities in a lymph node.
    Trimaldi JA; Bowers JW; Bello C; Sagatys EM
    Cancer Control; 2014 Jul; 21(3):251-4. PubMed ID: 24955711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas.
    Li T; Hiemstra IH; Chiu C; Oliveri RS; Elliott B; DeMarco D; Salcedo T; Egerod FL; Sasser K; Ahmadi T; Gupta M
    Clin Pharmacol Ther; 2022 Nov; 112(5):1108-1119. PubMed ID: 35996883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.